Emerging data indicate that an HIV vaccine could protect by inducing sufficient titers of broadly-neutralizing antibodies that mediate both direct viral neutralization as well as Fc-dependent effector functions against the diverse strains of HIV. Recent antibody discovery efforts have revealed a large number of new broadlyneutralizing monoclonal antibodies (bnMAbs) with extraordinary potency and breadth, raising the prospect that protective titers could be practically achieved if similar bnMAb specificities could be induced. vStructural studies of these new bnMAbs have revealed that they utilize structural and genetic features that appear to be unique to humans. We therefore propose to employ the humanized BLT mouse model to evaluate and optimize vaccines targeting new highly potent bnMAbs. BLT mice possess human humoral, cellular, and innate repertoires. We have demonstrated that the human immune system in these mice supports sustained HIV infection and generates human class-switched neutralizing antibodies in response. In this project, we propose to take a three-pronged approach to optimize vaccines targeting these new bnMAbs in the BLT mouse model, in Aim 1, we will develop a more complete understanding of the human antibody response to HIV infection generated in BLT mice, in order to utililize this model system most effectively for vaccine research, including for HIV vaccine challenge studies.
In Aim 2, we will develop a more complete understanding of the ability of bnMAbs to protect against HIV infection following passive transfer to BLT mice in vivo, comparing b12, for which protection has been documented in the established macaque SHIV challenge model, with the new more potent and broad bnMAbs targeted by our current vaccine design efforts. Using selectively mutated antibodies, we will also compare the relative protective contributions of the neutralizing activities of these antibodies to their Fc receptor-dependent effector functions.
In Aim 3, we will employ BLT mice to evaluate and optimize novel epitope-focused immunogens and immunization regimens designed to induce potent and broad bnMAbs like VRC01, targeting the CD4-binding site, and 10E8, targeting the membrane proximal external region.

Public Health Relevance

HIV is a major threat to global health and a vaccine is urgently needed. This project will evaluate HIV infection, protection against infection by passive administration of antibody, and vaccine-induced immune responses, in humanized mice with the ultimate goal of developing a protective HIV vaccine that induces broadly-neutralizing antibodies.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RRS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Pejawar-Gaddy, Sharmila; Kovacs, James M; Barouch, Dan H et al. (2014) Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination. Bioconjug Chem 25:1470-8
Liu, Haipeng; Moynihan, Kelly D; Zheng, Yiran et al. (2014) Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507:519-22
Körner, Christian; Granoff, Mitchell E; Amero, Molly A et al. (2014) Increased frequency and function of KIR2DL1-3? NK cells in primary HIV-1 infection are determined by HLA-C group haplotypes. Eur J Immunol 44:2938-48
Seung, Edward; Dudek, Timothy E; Allen, Todd M et al. (2013) PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One 8:e77780
Tager, Andrew M; Pensiero, Michael; Allen, Todd M (2013) Recent advances in humanized mice: accelerating the development of an HIV vaccine. J Infect Dis 208 Suppl 2:S121-4
Seung, Edward; Tager, Andrew M (2013) Humoral immunity in humanized mice: a work in progress. J Infect Dis 208 Suppl 2:S155-9
Lavender, Kerry J; Pang, Wendy W; Messer, Ronald J et al. (2013) BLT-humanized C57BL/6 Rag2-/-?c-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood 122:4013-20
Dudek, Timothy E; Allen, Todd M (2013) HIV-specific CD8ýýý T-cell immunity in humanized bone marrow-liver-thymus mice. J Infect Dis 208 Suppl 2:S150-4